Ventas, Inc. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing, not a standalone fourth-quarter report; the supplied filing text does not provide a clear set of Q4-only financial results.
Business context
Ventas is a healthcare real estate investment trust (REIT) with approximately 1,400 owned or invested-in properties across North America and the United Kingdom. Its three reportable segments are senior housing operating portfolio (SHOP), outpatient medical and research properties, and triple-net leased properties. The company reported 1,355 properties in its segment NOI table; the broader portfolio count also includes properties held for sale and investments.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Total revenue | $4.498 billion | $4.129 billion |
| Net loss attributable to common stockholders | $41.0 million; diluted loss per share $0.10 | $47.4 million; diluted loss per share $0.12 |
| NOI (non-GAAP) | $1.925 billion | $1.843 billion |
| Normalized FFO attributable to common stockholders (non-GAAP) | $1.212 billion | $1.207 billion |
| Cash provided by operating activities | $1.120 billion | $1.120 billion |
| Cash, cash equivalents and restricted cash at year-end | $563.5 million | $170.7 million |
| Interest expense | $574.1 million | $467.6 million |
| Principal indebtedness | $13.57 billion | $12.36 billion |
Segment NOI: SHOP generated $711.4 million (37% of total), outpatient medical and research $576.9 million (30%), and triple-net leased properties $604.7 million (31%). SHOP NOI rose 9.9%, outpatient medical and research NOI rose 5.5%, and triple-net NOI rose 3.7% year over year.
Operating indicators: SHOP average occupancy was 81.4%, versus 80.8% in 2022, and average monthly revenue per occupied room was $4,684, versus $4,396. Outpatient medical and research occupancy at year-end was 87.7%, versus 90.0% a year earlier. SHOP same-store NOI grew 8.7%; outpatient medical and research same-store NOI grew 2.0%; triple-net same-store NOI grew 1.6%.
Debt and liquidity: Year-end liquidity was approximately $3.2 billion, including cash and revolving-credit availability. The $2.75 billion revolver had $14.0 million drawn, and there were no commercial paper borrowings. Fixed-rate debt was $12.46 billion and variable-rate debt $1.11 billion; the weighted average effective interest rate was 4.23% for 2023, versus 3.66% in 2022. Scheduled 2024 maturities total $1.264 billion and 2025 maturities total $2.227 billion. The company reported compliance with debt covenants.
Dividends: Ventas declared $1.80 per common share for 2023, including $0.45 in the fourth quarter. Management expects to distribute at least 100% of taxable net income, after applicable net operating loss carryforwards, in 2024; the board sets dividends quarterly.
Material changes versus 2022
- Total revenue increased by $368.6 million, while NOI increased by $82.5 million. SHOP growth reflected improved occupancy and room revenue, portfolio conversions and properties obtained through the Santerre transaction.
- Normalized FFO increased modestly from $1.207 billion to $1.212 billion. Management notes that 2022 included $54.2 million of HHS grants and $9.9 million of Ventas Fund promote revenue; 2023 received no HHS grants.
- Interest expense rose $106.6 million, primarily due to higher effective borrowing rates and higher average debt balances. Depreciation and amortization rose $194.7 million, including higher impairment expense and depreciation on additional properties.
- GAAP net loss narrowed to $41.0 million from $47.4 million. 2023 included $62.1 million of gains on property dispositions, a $29.1 million gain on foreclosure of real estate, a $33.5 million gain from selling part of the Ardent investment, and an $8.3 million debt-extinguishment gain. Real estate impairments were $226.6 million, compared with $107.8 million in 2022.
- Cash from operations was essentially unchanged. Investing cash outflows fell to $184.7 million from $859.2 million, mainly reflecting fewer external acquisitions and higher disposition proceeds; financing cash outflows increased to $543.7 million.
Outlook, commentary and material risks
- Management expects senior housing to benefit from demographic demand, projecting U.S. population aged 80 and older to grow by more than 24% through 2029, while senior housing construction starts are at their lowest level since 2009. These are market expectations, not company earnings guidance.
- The filing gives no clear numerical 2024 outlook for revenue, NOI, FFO or earnings. Management says senior housing expense pressures may be moderating but cautions that this may not continue; inflation, labor costs, interest rates and broader economic conditions remain significant uncertainties.
- Lease renewals are a key near-term issue. Brookdale’s 121-property master lease expires December 31, 2025; its next 10-year renewal notice window is June–November 2024. Kindred’s lease for 23 properties expires April 30, 2025, with a renewal notice due before May 1, 2024. The filing identifies 2025 expirations representing $265.0 million of annualized base rent, or 42.8% of 2023 triple-net segment rental income.
- Tenant and manager concentration is material: Atria contributed 20.1% of total NOI; Sunrise 4.5%; Brookdale 7.7%; Ardent 6.9%; and Kindred 6.9%. Kindred property performance declined after pandemic-era elevated volumes, creating potential payment and renewal risk.
- Ventas took ownership of the Santerre collateral in May 2023 by converting its mezzanine loan to equity. The transaction involved real estate valued at $1.566 billion and a $1 billion senior mortgage, which Ventas repaid between June and August. Valuation assumptions for the transaction and SHOP impairments were identified as critical audit matters.
- The HHS Inspector General selected two of Ventas’s assisted-living grant applications for audit. The company believes it complied with requirements but cannot rule out repayment of some or all grants received in prior years.
- Ardent experienced a ransomware incident in November 2023 that disrupted some clinical and financial operations. Ventas said it had not identified a cybersecurity incident materially affecting, or reasonably likely to materially affect, Ventas itself.
- An activist investor nominated three board candidates in January 2024. The filing warns that responding may divert management attention and increase costs or stock-price volatility.
- Other principal exposures include healthcare regulation and reimbursement, labor availability and costs, property impairments, refinancing and capital-market access, interest-rate and currency movements, insurance adequacy, climate and catastrophic events, and maintaining REIT qualification.
Most important facts for investors to verify
- SHOP occupancy, resident revenue growth and labor/operating-cost trends, including whether same-store NOI gains persist without government grants.
- Brookdale’s 2024 renewal decision and Kindred’s renewal decision, tenant financial condition, and the company’s ability to re-lease or transition properties if leases are not renewed.
- Debt refinancing plans and costs for 2024–2026 maturities, variable-rate exposure, and continued access to revolver and capital markets.
- Santerre portfolio performance and valuation assumptions, future impairment exposure, and the resolution of the HHS grant audit.
- Effects of Ardent’s cyber incident, the activist campaign, and any changes to the 2024 dividend or management’s outlook.